Poseida Therapeutics Aktie (A2PEYK | PSTX

Was macht Poseida Therapeutics?

Unternehmensprofil

Poseida Therapeutics is a clinical-stage biopharmaceutical company utilizing genome engineering capabilities to develop targeted therapeutics for patients with high unmet medical needs. The company develops a pipeline of autologous and allogeneic chimeric antigen receptor T cell or CAR-T, product candidates focusing on the treatment of hematological malignancies and solid tumors.

Chart der Poseida Therapeutics Aktie

Charttool öffnen

Aktuelle Nachrichten zu Poseida Therapeutics

Weitere Nachrichten

Das berichten andere über Poseida Therapeutics

Poseida Therapeutics Aktie: Potenzial wird voll ausgeschöpft!

Poseida Therapeutics verzeichnete im Jahr 2024 einen bemerkenswerten finanziellen Erfolg mit einem Jahresüberschuss von 1,4 Milliarden USD. Der Biotechnologiekonzern, der...

Roche to complete acquisition of U.S. biopharma company Poseida

Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics via its subsidiary Blue Giant Acquisition Corp.

Roche set to finalise $1.5bn Poseida Therapeutics takeover

Swiss healthcare firm Roche has said its US$1.5 billion takeover of US biopharmaceutical company Poseida Therapeutics will be completed on Wednesday. Roche...

Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash

Basel, 9 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of Poseida...